MarketCap
Facebook
X
TelegramAnnual report 2023
added 02-29-2024
PetIQ Operating Income 2011-2026 | PETQ
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income PetIQ
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 37.1 M | -20.2 M | 15.9 M | -3.19 M | -3.14 M | 7.75 M | 13.3 M | 702 K | 3.57 M | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 37.1 M | -20.2 M | 5.75 M |
Quarterly Operating Income PetIQ
| 2023-Q3 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.36 M | - | -42.5 M | 11.4 M | 9.4 M | - | -3.18 M | 16.5 M | 7.13 M | - | -3.29 M | 3.69 M | 464 K | -12.6 M | -4.36 M | 8.99 M | 4.87 M | -4.85 M | 6.91 M | 8.92 M | -3.23 M | 42 K | 1.78 M | 6.67 M | 4.8 M | 116 K | -1.78 M | 659 K | 1.71 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 16.5 M | -42.5 M | 1.06 M |
Operating Income of other stocks in the Drug manufacturers industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agile Therapeutics
AGRX
|
-19.9 M | - | 10.11 % | $ 58.2 M |  USA |
 |
AcelRx Pharmaceuticals
ACRX
|
-13.5 M | - | 7.5 % | $ 6.35 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.1 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-46.4 M | - | - | $ 754 M | USA |
 |
Catalent
CTLT
|
-749 M | - | - | $ 11.5 B | USA |
 |
DURECT Corporation
DRRX
|
-36.9 M | - | - | $ 50.1 M | USA |
 |
Alimera Sciences
ALIM
|
-1.93 M | - | - | $ 142 M | USA |
 |
Athenex
ATNX
|
-70 M | - | -23.39 % | $ 1.76 M | USA |
 |
Eagle Pharmaceuticals
EGRX
|
81 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
-469 M | - | - | $ 28.9 M |  Irlanda |
 |
Avadel Pharmaceuticals plc
AVDL
|
-42.4 M | - | - | $ 2.06 B |  France |
 |
Evoke Pharma
EVOK
|
-7.43 M | - | - | $ 36.6 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
-1.84 M | $ 3.12 | 0.97 % | $ 43.9 M | USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-524 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
HEXO Corp.
HEXO
|
-85.5 M | - | 2.45 % | $ 38.1 M |  Canada |
 |
Bausch Health Companies
BHC
|
963 M | $ 5.72 | 2.14 % | $ 2.09 B | Canada |
 |
Harrow Health
HROW
|
30.5 M | $ 37.1 | 3.26 % | $ 1.36 B | USA |
 |
Aurora Cannabis
ACB
|
-283 M | $ 3.48 | 1.46 % | $ 86.3 M | Canada |
 |
Canopy Growth Corporation
CGC
|
-117 M | $ 1.08 | 2.86 % | $ 116 M | Canada |
 |
OrganiGram Holdings
OGI
|
-91.8 M | $ 1.42 | 1.43 % | $ 402 M | Canada |
 |
Neoleukin Therapeutics
NLTX
|
-103 M | - | - | $ 193 M | Canada |
 |
Relmada Therapeutics
RLMD
|
-59.1 M | $ 7.38 | 1.23 % | $ 291 M | USA |
 |
Lannett Company
LCI
|
-176 M | - | 1.15 % | $ 7.11 M | USA |
 |
Evolus
EOLS
|
-32.7 M | $ 4.33 | 1.41 % | $ 279 M | USA |
 |
Emergent BioSolutions
EBS
|
-726 M | $ 8.24 | 3.52 % | $ 422 M | USA |
 |
Sundial Growers
SNDL
|
-132 M | $ 1.37 | -3.52 % | $ 3.37 M | Canada |
 |
Tilray
TLRY
|
-1.37 B | $ 6.72 | 2.28 % | $ 4.15 B | Canada |
 |
Organogenesis Holdings
ORGO
|
-1.28 M | $ 2.38 | - | $ 313 M | USA |
 |
Pacira BioSciences
PCRX
|
-73.4 M | $ 24.06 | 1.13 % | $ 1.11 B | USA |
 |
Veru
VERU
|
-36.9 M | $ 2.38 | - | $ 321 M | USA |
 |
Viatris
VTRS
|
766 M | $ 13.83 | 2.67 % | $ 16.6 B | USA |
 |
ProPhase Labs
PRPH
|
23.6 M | - | - | $ 5.07 M | USA |
 |
cbdMD
YCBD
|
-3.32 M | $ 0.75 | 9.54 % | $ 3.23 M | USA |
 |
Assertio Holdings
ASRT
|
-21.5 M | $ 18.02 | - | $ 115 M | USA |
 |
Radius Health
RDUS
|
-54.3 M | - | - | $ 1.42 B | USA |
 |
Recro Pharma
REPH
|
-3.57 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-22.7 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-16.1 M | $ 1.01 | 1.0 % | $ 50.4 M | USA |
 |
PLx Pharma
PLXP
|
-40.8 M | - | -27.8 % | $ 2.56 M | USA |
 |
Solid Biosciences
SLDB
|
-179 M | $ 8.39 | 4.61 % | $ 734 M | USA |
 |
Sonoma Pharmaceuticals
SNOA
|
-3.71 M | $ 2.35 | 3.07 % | $ 2.92 M | USA |
 |
Zomedica Corp.
ZOM
|
-84.4 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-35.3 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-4.69 M | $ 0.94 | 3.31 % | $ 33.8 M | USA |
 |
Tricida
TCDA
|
-153 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
-3.24 M | $ 0.65 | 0.6 % | $ 2.79 M |  China |
 |
TherapeuticsMD
TXMD
|
-4.39 M | $ 2.05 | -0.97 % | $ 23.7 M | USA |